Provided by Tiger Trade Technology Pte. Ltd.

JUNSHI BIO

17.140
-0.500-2.83%
Volume:1.44M
Turnover:24.56M
Market Cap:17.60B
PE:-19.70
High:17.630
Open:17.460
Low:17.030
Close:17.640
52wk High:37.960
52wk Low:15.250
Shares:1.03B
HK Float Shares:260.00M
Volume Ratio:0.88
T/O Rate:0.55%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.870
ROE:-9.32%
ROA:-2.23%
PB:2.53
PE(LYR):-19.70
PS:4.98

Loading ...

Shareholder Offloads Nearly 7 Billion Yuan in Precision-Timed Selloff, Stake Drops to 3.79%

Deep News
·
Aug 21

JUNSHI BIO Sets 26 August 2026 Board Meeting to Review 1H 2026 Results

Bulletin Express
·
Aug 12

Junshi Biosciences Shareholder Cuts Stake

MT Newswires Live
·
Aug 11

JUNSHI BIO Shareholder He Ming Completes Sale of 882,600 Shares, Fulfilling Reduction Plan

Stock News
·
Aug 10

Junshi Biosciences Completes 300 Million Yuan Second Tranche Bond Issue

MT Newswires Live
·
Jul 23

Shanghai Junshi's Toripalimab Supplemental Application Accepted in China

MT Newswires Live
·
Jul 22

Shanghai Junshi Biosciences Gets NMPA Acceptance Notice of Supplemental Application for Toripalimab

Reuters
·
Jul 22

Shanghai Junshi Biosciences - Acceptance of Supplemental Application for Toripalimab in Combination with Chemotherapy as Perioperative Treatment

THOMSON REUTERS
·
Jul 21

Shanghai Junshi Biosciences - Acceptance Notice Issued by Nmpa China

THOMSON REUTERS
·
Jul 21

Zhongou Fund's Ge Lan Q2 Report Revealed: Junshi Bio Enters Top Holdings, Kelun Pharma Sees Major Increase

Deep News
·
Jul 21

HK Movers | Biomedical Stocks Rally; REMEGEN, WUXI XDC and KEYMED BIO-B Surge Over 8%

Tiger Newspress
·
Jul 20

JUNSHI BIO Shares Surge Over 5% on Inclusion of Junmaikang® in National Essential Drug List

Stock News
·
Jul 10

JUNSHI BIO Seeks Shareholders’ Nod for 10% H-Share Buyback Mandate

Bulletin Express
·
Jul 08

Junshi Biosciences to Seek H-Share Repurchase Mandate at 27 July 2026 EGM

Bulletin Express
·
Jul 08

Junshi Biosciences Sets 22–27 July 2026 H-Share Register Closure to Confirm First EGM Entitlements

Bulletin Express
·
Jul 08

Possible Turnaround For Shanghai Junshi Biosciences Insiders, Still Down CN¥4.6m

Simply Wall St.
·
Jul 05

Junshi Bio June 2026 Monthly Return: Share Capital Unchanged, 37.91 Million Options Outstanding

Bulletin Express
·
Jul 03

Shanghai Junshi Biosciences HK Shares Hit 4-week Peak on Fosun's Licensing Deal

Reuters
·
Jul 02

JUNSHI BIO Shares Surge Over 11% on Licensing Agreement for Novel Antibody

Stock News
·
Jul 02

Junshi Biosciences licenses anti-IL-17A antibody “Roconkibart” to Fosun Wanbang in RMB1.34 billion deal for Greater China

Bulletin Express
·
Jul 01